Holen Sie sich die Stockscreener-App
10.92
2.72%
-0.28
Schlusskurs vom Vortag:
$11.20
Offen:
$11.22
24-Stunden-Volumen:
355.70K
Relative Volume:
0.24
Marktkapitalisierung:
$1.40B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.86M
KGV:
-29.41
EPS:
-0.3713
Netto-Cashflow:
$-44.02M
1W Leistung:
-18.08%
1M Leistung:
+4.76%
6M Leistung:
+32.06%
1J Leistung:
+73.21%
1-Tages-Spanne:
$10.88
$11.42
1-Wochen-Bereich:
$10.79
$13.29
52-Wochen-Spanne:
$4.85
$14.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
10.92 | 1.44B | 0 | -45.86M | -44.02M | -0.3713 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.37 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.22 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.32 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.61 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.49 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Rosalind Advisors Inc. Trims Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics at Leerink Global: Strategic Cough Treatment Advances By Investing.com - Investing.com Canada
Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control (NASDAQ:TRVI) - Seeking Alpha
Zacks.com featured highlights include Trevi, Metalla Royalty & Streaming and Vermilion - The Globe and Mail
Zacks.com spotlighted features include Trevi, Metalla Royalty & Streaming, and Vermilion - Bitget
Q4 and year end 2025 earnings call announced, Trevi Therapeutics outlines - Traders Union
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026 - WFMZ.com
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - MarketBeat
Oppenheimer Maintains Outperform on TRVI (March 09, 2026) - Meyka
Trevi Therapeutics (TRVI) Secures FDA Support for Advanced Clini - GuruFocus
Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials - TipRanks
Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March - The Globe and Mail
Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from D. Boral Capital - MarketBeat
TRVI: D. Boral Capital Maintains Buy Rating with $19 Target | TR - GuruFocus
Trevi Therapeutics stock gets Oppenheimer nod on Phase 3 plans By Investing.com - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 9.9%Here's What Happened - MarketBeat
Trevi Therapeutics (TRVI) Advances with Phase 3 Trials for Haduv - GuruFocus
HC Wainwright Reiterates Buy Rating for Trevi Therapeutics (TRVI) at $21 | TRVI Stock News - GuruFocus
Trevi Therapeutics' (TRVI) Buy Rating Reiterated at HC Wainwright - MarketBeat
TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns - Stocktwits
Trevi Therapeutics (TRVI) has successfully completed the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). - Bitget
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough - Bitget
Trevi Therapeutics Announces Completion of End-of-Phase 2 - GlobeNewswire
How supply chain issues affect Trevi Therapeutics Inc. stock2025 Year in Review & Technical Pattern Based Signals - Naître et grandir
Stock Recap: Can Trevi Therapeutics Inc continue delivering strong returnsWeekly Investment Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Earnings Recap: Is Trevi Therapeutics Inc stock technically oversoldQuarterly Profit Report & Accurate Buy Signal Alerts - baoquankhu1.vn
Inflation Data: Can Trevi Therapeutics Inc continue delivering strong returnsPortfolio Performance Report & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Can Trevi Therapeutics Inc continue delivering strong returnsQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
Value Recap: Can Trevi Therapeutics Inc continue delivering strong returnsJuly 2025 Chart Watch & Advanced Technical Signal Analysis - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. Senior Management to Present at 2026 Healthcare Conferences - Quiver Quantitative
Chronic cough treatment talks: Trevi execs head to Miami and Philly in March - Stock Titan
MAI Capital Management Cuts Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Assessing Trevi Therapeutics (TRVI) Valuation After Strong Long Term Returns And A Rich Price To Book Ratio - Yahoo Finance
TRVI Should I Buy - Intellectia AI
TRVI PE Ratio & Valuation, Is TRVI Overvalued - Intellectia AI
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Promising 87% Potential Upside Captures Investor Attention - DirectorsTalk Interviews
TRVI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect? - Finviz
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Trevi Therapeutics (TRVI) officer receives 35,000-share stock option grant - Stock Titan
Executive at Trevi (NASDAQ: TRVI) granted 160,000 stock options - Stock Titan
Trevi Therapeutics (TRVI) CSO awarded stock options on 85,000 shares - Stock Titan
Will Trevi Therapeutics Inc. outperform its industry peersJuly 2025 Volume & AI Driven Stock Price Forecasts - mfd.ru
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Trevi Therapeutics Executives to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Promising 99% Potential Upside In Biotech - DirectorsTalk Interviews
Can Trevi Therapeutics Inc. disrupt its industryDay Trade & Safe Investment Capital Preservation Plans - mfd.ru
Is Trevi Therapeutics Inc. stock resilient to inflationGold Moves & Fast Entry High Yield Stock Tips - mfd.ru
New Haven biotech Trevi Therapeutics builds billion-dollar valuation around lone late-stage cough drug - Hartford Business Journal
Fed Watch: Can Trevi Therapeutics Inc continue delivering strong returns2025 Market Trends & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):